Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS' skin cancer drug

The US Food and Drug Administration has approved Bristol-Myers Squibb's Yervoy for the treatment of unresectable or metastatic melanoma

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's (BMS) Yervoy (ipilimumab) for the treatment of unresectable or metastatic melanoma.

The drug is the first approved therapy in the US that demonstrates a 'significant improvement' in overall survival for patients whose skin cancer cannot be treated with surgery or has spread to other organs.

The decision date for approval had been moved back from December 25, 2010, with the FDA determining that additional time was required to complete the review of the biologics licence application.

Yervoy recently showed positive results from a phase III study that compared the drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

Lamberto Andreotti, CEO, BMS said: "Today's approval of Yervoy is an example of Bristol-Myers Squibb living its mission of developing and delivering innovative medicines that address the unmet needs of patients with serious diseases."

BMS has said it expects to begin shipment of Yervoy within weeks.

A post-marketing study will also be carried out comparing the safety and efficacy of the 3mg/kg dose of the drug against an investigational 10mg/kg dose.

28th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Digital disruption
How pharma is keeping up with the pace of change...
The new pharma marketing playbook
Learn about the 5 areas that must be in your pharma marketing playbook...
Pharma needs to evolve from customer-centricity to stakeholder-centricity
Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....

Infographics